Summary: Yttrium-90 Edotreotide (also known as Yttrium-90 DOTATOC or Yttrium-90 Onalta®) is a radiopharmaceutical that was once considered a leading contender in the targeted therapy of neuroendocrine tumours (NETs). It links a radioisotope (Yttrium-90) with the somatostatin analogue edotreotide, enabling targeted delivery of radiation to somatostatin receptor-expressing cells. Clinical trials showed that it could produce up to 30% partial and complete responses in patients with NETs. Although Yttrium-90 Edotreotide reached Phase II, it was eventually eclipsed by more effective Lutetium-177-based therapies. However, with the patent having expired in 2015, renewed developments and forthcoming authorisations for 177Lu-Edotreotide (Solucin) mean that its legacy remains relevant to current and future therapeutic strategies for NETs.
Keywords: Yttrium-90 Edotreotide; Neuroendocrine Tumours; Somatostatin Receptors; Targeted Radionuclide Therapy; Kidney Toxicity; Radiopharmaceuticals.
Introduction to Yttrium-90 Edotreotide
Yttrium-90 Edotreotide (commonly referred to by its chemical synonyms, such as 90Y-DOTATOC or Onalta®) is a radiotherapeutic agent designed to target somatostatin receptors (SSTRs) on neuroendocrine tumours (NETs). Neuroendocrine tumours comprise a diverse group of malignancies that arise from neuroendocrine cells found throughout the body, frequently in the gastrointestinal tract or the pancreas. These tumours often express high levels of somatostatin receptors, a feature exploited by radionuclide therapies for precise targeting.
The rationale behind the development of Yttrium-90 Edotreotide was straightforward: harness the targeting specificity of a somatostatin analogue (edotreotide) to deliver a potent β-emitting isotope (Yttrium-90) directly to the tumour, thereby maximising efficacy and limiting damage to healthy tissues. This approach revolutionised the management of NETs by improving tumour response rates and extending progression-free survival in some patients. Early-phase clinical trials offered encouraging results, including stable disease, partial responses, and complete remission in a subset of cases.
Although Yttrium-90 Edotreotide demonstrated considerable promise, it faced challenges when Lutetium-177 (177Lu)-based therapies emerged, showing potentially higher efficacy and a safer toxicity profile. While 90Y-Edotreotide progressed through Phase II clinical trials and was considered the most advanced radio-labelled somatostatin analogue, the shift towards 177Lu-labelling caused 90Y-Edotreotide research and development to slow significantly. Nevertheless, it remains a critical milestone in the field of targeted radionuclide therapy. The drug’s patent expired in September 2015 in Europe, opening the possibility for alternative developments. Current attention is also focusing on 177Lu-Edotreotide (Solucin), which may continue the legacy begun by Yttrium-90 Edotreotide.
Mechanism of Action and Target
Neuroendocrine tumours have a particular affinity for somatostatin, a hormone that regulates endocrine and neuronal functions across different organ systems. Most NETs express somatostatin receptor subtypes, notably SSTR2, which has a high affinity for somatostatin analogues such as octreotide and edotreotide. By attaching a radioactive isotope to these analogues, clinicians can selectively deliver a cytotoxic dose of radiation to tumour cells.
Edotreotide: A Versatile Ligand
Edotreotide is a derivative of octreotide, designed to maintain a strong binding affinity for SSTRs while also supporting the conjugation of a chelating agent, DOTA (tetraazacyclododecanetetraacetic acid). The DOTA ring securely holds the radioactive Yttrium-90 ion (90Y3+), preventing premature release of the radioisotope into the bloodstream. Once bound to the tumour cell, the radiopharmaceutical is internalised, enabling high doses of β-radiation to be deposited within the tumour microenvironment. This targeted effect is essential for therapeutic efficacy, aiming to destroy malignant cells while sparing normal tissues as much as possible.
The Role of Beta Electrons (β–)
Yttrium-90 is a pure β-emitter with an average energy of approximately 0.93 MeV. These beta particles have a moderate tissue penetration range, delivering radiation within a few millimetres. This localisation is both a strength and limitation: it can kill tumour cells within that range but may leave some tumour regions insufficiently irradiated if they lie beyond the particle’s maximum penetration depth. The therapy’s success depends heavily on tumour size, distribution, and, crucially, the retention time of the radio-labelled analogue within the tumour tissue.
Clinical Efficacy and Trials
Initial clinical evaluations of Yttrium-90 Edotreotide occurred in the late 1990s and early 2000s. Phase I and II studies aimed to establish the maximum tolerated dose and evaluate the agent’s efficacy in patients with advanced NETs. Researchers observed encouraging results, including disease stabilisation in many participants and objective response rates—partial or complete—of up to 30%. These outcomes were particularly notable for patients whose tumours were non-resectable or resistant to standard chemotherapy.
Phase II Results
By 2009, Yttrium-90 Edotreotide had completed Phase II trials, confirming both its anti-tumour activity and its toxicity profile. The kidney emerged as the critical organ at risk, followed by bone marrow suppression, underscoring the need for renal protection protocols such as amino acid co-infusion. Nevertheless, the outcomes indicated that the treatment was an important addition to the limited therapeutic arsenal for metastatic NETs.
Competing with Lutetium-177 Analogues
A significant turning point occurred when Lutetium-177-labelling (e.g., 177Lu-DOTATATE, 177Lu-Edotreotide) demonstrated higher clinical efficacy, better tumour penetration, and a more favourable safety profile, particularly for large tumours. Lutetium-177 has a lower average beta energy and emits gamma photons, facilitating post-therapy imaging. This innovation improved patient monitoring, dosage calculation, and overall therapeutic outcomes. As a result, 90Y-Edotreotide research took a backseat. Although 90Y-Edotreotide was more developed at one time, most centres began shifting to 177Lu-based therapies or a customised combination of 90Y- and 177Lu-labelled somatostatin analogues to achieve optimal tumour coverage.
Toxicity and Safety Considerations
One of the main concerns with Yttrium-90 Edotreotide, as with many peptide receptor radionuclide therapies, is nephrotoxicity. The kidneys receive a substantial amount of the radiolabelled peptides through glomerular filtration and tubular reabsorption. Over time, the accumulation of radiation in the renal parenchyma can lead to chronic kidney damage. This risk is mitigated by administering protective amino acid infusions to reduce renal uptake of the radiopharmaceutical. Treatment protocols also carefully consider the cumulative dose scheduling therapies to minimise long-term renal impairment.
Bone Marrow Suppression
Another notable side effect is myelosuppression, or a decrease in bone marrow activity leading to reduced counts of white blood cells, red blood cells, and platelets. This can increase susceptibility to infections, fatigue, and bleeding complications. Monitoring blood counts and adjusting therapy accordingly helps to prevent severe haematological side effects.
Other Considerations
Beyond kidney and bone marrow toxicity, Yttrium-90 Edotreotide therapy can produce general side effects, including nausea, vomiting, fatigue, and transient hormonal imbalances. Patients require close supervision to detect any acute or delayed adverse events. Regular follow-up imaging is also necessary to ascertain therapeutic effectiveness and rule out complications such as radiation-induced secondary malignancies—albeit rare.
Current Status and Alternatives
Yttrium-90 Edotreotide reached an advanced stage of clinical investigation before the rise of Lutetium-177 therapies. After showing promise in Phase II trials, its development was placed on hold, primarily because it became evident that 177Lu-labelling offered substantial benefits. Moreover, the patent for 90Y-Edotreotide expired in September 2015 in Europe, meaning it no longer holds exclusivity. Although this could theoretically open avenues for generic versions or renewed interest, the field has moved decisively towards 177Lu-based options.
177Lu-Oxodotreotide (177Lu-DOTATATE)
Currently, the market leader in treating metastatic or inoperable NETs is Lutetium-177-based therapy, specifically 177Lu-Oxodotreotide (also known as 177Lu-DOTATATE or Lutathera®). It gained regulatory approval in Europe and the United States for gastroenteropancreatic NETs and has shown remarkable success in prolonging progression-free survival. Its relatively favourable safety profile, combined with improved imaging capabilities, has made it the preferred choice in many nuclear medicine centres.
177Lu-Edotreotide (Solucin)
An additional alternative is 177Lu-Edotreotide, branded as Solucin, which aims to build on the success of 177Lu-labelling by pairing it with edotreotide. When this radiopharmaceutical obtains marketing authorisation, it may offer an expanded set of therapeutic options for NET patients, possibly improving the targeting and retention seen with 177Lu-based therapies. The structure is analogous to 90Y-Edotreotide in that it utilises the same peptide ligand, but it employs 177Lu for its radioisotope. This could provide similar or improved receptor affinity with potentially enhanced imaging properties compared to Yttrium-90.
Potential for Combined Radionuclide Therapy
Notably, some treatment centres explore the concept of combining both 90Y- and 177Lu-based therapies, tailoring doses according to tumour size and distribution. Larger tumour lesions may benefit from the higher-energy beta emission of 90Y, while smaller lesions or microscopic diseases respond well to 177Lu’s shorter path length. This multi-radionuclide approach is usually considered experimental and requires careful dosimetric planning to avoid exacerbating toxicity.
Patent Expiry and Future Outlook
With Yttrium-90 Edotreotide’s European patent having expired in September 2015, there is no longer a single entity holding exclusive rights to its commercial development. Theoretically, this opens the door to generics or improved formulations. However, interest in 90Y-Edotreotide has waned as 177Lu-based analogues demonstrate superior clinical outcomes. It is not unusual for older therapies to find niche applications in particular patient groups. Still, widespread adoption is unlikely unless new comparative data emerges demonstrating benefits over or synergy with 177Lu-based treatments.
Personalised Medicine Approaches
Emerging trends in oncology lean towards personalised medicine, where patients receive treatments tailored to their genetic, molecular, and clinical profiles. In principle, 90Y-Edotreotide could still play a role for certain subtypes of NETs or certain tumour sizes that are more amenable to the longer-range beta emissions of 90Y. Advances in molecular imaging and companion diagnostics may provide better identification of patients who would respond optimally to 90Y-based therapy. In parallel, new forms of tumour dosimetry, including software-based approaches to map radioisotope distribution, could refine how treatments are planned.
Combination with Immunotherapies
Researchers continue to investigate strategies to enhance the effects of targeted radionuclide therapies through combination with immunotherapies. Immune checkpoint inhibitors, for instance, could synergistically boost tumour-killing by modulating the tumour microenvironment. If 90Y-Edotreotide is reintroduced into clinical practice, combining it with these newer agents might yield novel therapeutic pathways for refractory NETs. However, any such combination would require robust evidence from well-designed clinical trials.
Future Directions
With regulatory and commercial attention primarily focused on Lutetium-177-based therapies, the immediate future for Yttrium-90 Edotreotide remains uncertain. That said, its fundamental design—targeting somatostatin receptors with a potent β-emitter—remains a valid strategy. An optimal scenario might involve using 90Y-labelling in combination with other isotopes or employing updated formulations that reduce nephrotoxicity. At present, many nuclear medicine centres and pharmaceutical entities have shifted their resources towards 177Lu-based and even alpha-emitting therapies, which hold promise for achieving a higher therapeutic index.
Conclusion
Yttrium-90 Edotreotide is an important chapter in the history of targeted radionuclide therapy for neuroendocrine tumours. By coupling a somatostatin analogue (edotreotide) with a beta-emitting radioisotope (Yttrium-90), it paved the way for more sophisticated radiopharmaceuticals that could deliver high doses of radiation directly to tumours. Early clinical trials demonstrated meaningful rates of partial and complete responses, as well as disease stabilisation in a significant proportion of NET patients. The therapy’s limitations, however—particularly renal toxicity and the difficulties of monitoring pure beta-emission—prompted the oncological community to pursue alternatives, culminating in the success of Lutetium-177-labelling.
The kidney and bone marrow remain the key organs at risk, emphasising the importance of nephroprotection and vigilant haematological monitoring. After completing Phase II trials in 2009, Yttrium-90 Edotreotide was largely set aside once 177Lu analogues displayed a better safety and efficacy profile. The European patent’s expiry in 2015 could have reignited interest, but most researchers and clinicians now favour 177Lu-based radiopharmaceuticals. Nevertheless, the future might see renewed exploration of 90Y-labelling in the context of personalised medicine, combination strategies, or special tumour scenarios where its longer-range beta emissions provide a unique advantage.
Although clinical and research efforts have gravitated away from Yttrium-90 Edotreotide, the knowledge and techniques developed through its trials persist in the next generation of therapies. The upcoming 177Lu-Edotreotide (Solucin) illustrates how the legacy of 90Y-Edotreotide lives on, guiding contemporary treatment paradigms for neuroendocrine tumours. Moreover, the emergence of alpha-emitters and other innovative approaches signals a rapidly evolving landscape in which targeted radionuclide therapies continue to refine and expand, offering hope for more effective and personalised cancer treatments.
Yttrium-90 Edotreotide’s journey—from a pioneering approach to a stepping stone for superior 177Lu-based strategies—exemplifies the dynamic nature of cancer research, where incremental advances in safety and efficacy reshape the standards of care. In the broader context of NET treatment, its historical role remains a testament to the enduring importance of targeted radiopharmaceuticals and a reminder that scientific progress often builds upon the achievements of earlier breakthroughs.
You are here: home »